RxDoctor Payments Data

Shannon Byrd, MD

Pulmonary Disease · Knoxville, TNNPI 1265477400

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $17,348 of the $23,207 with a category attached, or 74.8%. It is spread thinly across 45 manufacturers, the largest accounting for just 21.8%. 2025 is the largest year on record at $8,351, 2.3 times the $3,645 reported in 2019.

$23,207in general payments, 2019–2025

Across 814 payments — averaging $28.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$5K
  • AstraZeneca$4K
  • GSK$3K
  • Insmed, Inc.$2K
  • Boehringer Ingelheim$1K
  • Covidien LP$1K
  • plus $7K from 39 others

What the payments were for

  • Consulting fees$4,32019%
  • Travel & lodging$1,3196%
  • Food & beverage$17,34875%
  • Education$2201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,207 in reported general payments places this provider in the 85th percentile of 339 pulmonary disease providers in Tennessee.

See all pulmonary disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$827,337
Medicare patients
456
Services billed
14,730

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate36$447,206
Trelegy ElliptaFluticasone/Umeclidin/Vilanter332$288,469
Spiriva RespimatTiotropium Bromide129$96,825
Breztri AerosphereBudesonide/Glycopyr/Formoterol91$69,710
Breo ElliptaFluticasone/Vilanterol104$64,243
SymbicortBudesonide/Formoterol Fumarate83$27,845
Stiolto RespimatTiotropium Br/Olodaterol Hcl48$26,376
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$13,264
Fluticasone-SalmeterolFluticasone Propion/Salmeterol46$11,945
Advair HfaFluticasone Propion/Salmeterol23$11,604
EliquisApixaban15$10,388
Arnuity ElliptaFluticasone Furoate35$9,879
Albuterol Sulfate HfaAlbuterol Sulfate266$9,147
Spiriva HandihalerTiotropium Bromide13$6,271
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate25$5,047

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$1,422$570,408213 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$2,762$375,855484 claims
AstraZenecaBreztri Aerosphere, Symbicort$3,625$97,556174 claims
PfizerEliquis$39$10,38815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 339 pulmonary disease providers in Tennessee.

Other pulmonary disease in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →